Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma.

Danai Samutpradit¹, Phurin Areesawangkit¹, Pranaidej Hengswat¹, Wannasiri Chiraphapphaiboon¹, Ployploen Phikulsod¹, Kornkan Choome¹, Nattaporn Phanthaphol¹, Yupanun Wutti-In¹, Mutita Junking¹, Sanya Sukpanichnant², Thaweesak Chieochansin^3,4, Pa-Thai Yenchitsomanus⁵

¹Siriraj Center of Research Excellence for Cancer Immunotherapy and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

²Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

³Siriraj Center of Research Excellence for Cancer Immunotherapy and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; thaweesak.chieochansin@gmail.com.

⁴Computational and Genomic Hematology Group (GrHeCo-Xen), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

⁵Siriraj Center of Research Excellence for Cancer Immunotherapy and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; pathai.yen@mahidol.edu.

PubMed DOI

Abstract

BACKGROUND/AIM: Multiple myeloma (MM) remains incurable due to relapse and therapeutic resistance. This study evaluated the cancer-testis antigen NY-ESO-1 as a target for T-cell-based immunotherapy and assessed the potential of a self-differentiated monocyte-derived dendritic cell platform expressing NY-ESO-1 (SD-DC-NY) to activate T-lymphocytes against MM in vitro. MATERIALS AND METHODS: NY-ESO-…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.